Our Technology
Where Molecular Diagnostics meets Cutting Edge Lab-on-chip Technology
Scalable Molecular Diagnostics:
Unprecedented Turnaround Time with Pristine Sensitivity
Zepto utilizes Giant Magnetoresistance (GMR), a 2007 Nobel prize winning technological development to bring cutting edge diagnostic precision to the point of care.
Zepto's technology leverages GMR technology to achieve an astonishing molecular sensitivity of
>95%
Zepto's technology can achieve higher sensitivity with a turnaround time of
<90min
Zepto's innovations will allow for 36-plex uninterfered multiplex molecular detection
>=36
Zepto's FungiFlex™ Panel
Diagnostics in minutes, not days
Actionable results in hours
LIS Integrated workflow
Lab-on-a-chip diagnostics
*This device has not been evaluated, cleared or approved for use by the FDA, and is not for sale in the U.S.
Fully automated assay
> 95% of U.S. fungal pathogens
Minimally invasive sample
Near-patient testing
Bypasses the need for cultures
All reagents embedded
Lab-on-a-chip diagnosis
Actionable results in 90 minutes
Sample-to-result workflow
Automated results exporting
Air-gapped secure system
The Hidden Pandemic
The Problem with IFIs
Deaths attributed to IFIs
each year worldwide
Fungal infections often go undiagnosed or misdiagnosed, leading to delayed treatment and increased mortality.
Despite their severity, fungal diseases receive limited global attention and funding compared to other infectious diseases.
Improved awareness, rapid diagnostics, and access to antifungal treatments are essential to reducing the global burden of these life-threatening infections.
In direct medical costs
are associated with IFIs in the U.S.
Fungal infections disproportionately impact vulnerable populations, such as immunocompromised patients, leading to higher treatment complexity and cost.
Many of these infections are difficult to diagnose early, resulting in disease progression that requires more aggressive and expensive interventions.Immunocompromised individuals are more likely to develop invasive fungal diseases that can be life-threatening if not diagnosed and treated promptly.
People at high risk for IFIs
in the U.S. alone
Immunocompromised individuals are more likely to develop invasive fungal diseases that can be life-threatening if not diagnosed and treated promptly.
Invasive fungal infections in these patients are associated with high mortality rates, often exceeding 50% when not promptly treated. Despite these dangers, awareness remains low, contributing to delayed diagnosis.
Comparative Advantages
Built for Any Assay
GMR technology offers more effective & efficient detection over traditional fluorescence methods
Lab-on-a-chip technology allows for automated workflow with minimal manual requirements
Modular & customizable design allows for scalability with future diagnostic applications
Proprietary GMR-based assay allows for 36-sensorarray multiplexed
target detection
Zepto’s technology provides a turnaround time of < 90 minutes without foregoing quality
GMR allows for higher
signal to noise ratio
compared to autofluorescence.
High resolution
melting differentiates
non-specific bonding
via thermal stress
GMR technology offers more effective & efficient detection over traditional fluorescence methods
Lab-on-a-chip technology allows for automated workflow with minimal manual requirements
Modular & customizable design allows for scalability with future diagnostic applications
Proprietary GMR-based assay allows for 36-sensorarray multiplexed
target detection
Zepto’s technology provides a turnaround time of < 90 minutes without foregoing quality
GMR allows for higher
signal to noise ratio
compared to autofluorescence.
High resolution
melting differentiates
non-specific bonding
via thermal stress
Get In Touch
If you would like to learn more about our technology or would like to join our
team, don’t be afraid to reach out!
Zepto is always looking to incorporate promising new talent into our pool of
dedicated & passionate innovators. Send us a message today!
